shutterstock-179810984-web
360b / Shutterstock.com
5 January 2015Americas

FDA gives nod to Novartis cancer biosimilar

The US Food and Drug Administration (FDA) has recommended that an application by pharmaceutical company Novartis to market a biosimilar version of Amgen’s cancer drug Neupogen (filgrastim) be approved.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
29 July 2014   US officials have accepted an application by Novartis to market a biosimilar of Amgen’s Neupogen (filgrastim) drug, a move thought to be the first of its kind.
Biotechnology
26 July 2021   A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.

More on this story

Americas
29 July 2014   US officials have accepted an application by Novartis to market a biosimilar of Amgen’s Neupogen (filgrastim) drug, a move thought to be the first of its kind.
Biotechnology
26 July 2021   A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.

More on this story

Americas
29 July 2014   US officials have accepted an application by Novartis to market a biosimilar of Amgen’s Neupogen (filgrastim) drug, a move thought to be the first of its kind.
Biotechnology
26 July 2021   A California jury has ordered Novartis to pay $178 million to rival drugmaker Daiichi Sankyo for willfully infringing two cancer drug patents.